Compare ASTRAZENECA PHARMA with TTK HEALTHCARE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs TTK HEALTHCARE - Comparison Results

ASTRAZENECA PHARMA     Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA TTK HEALTHCARE ASTRAZENECA PHARMA/
TTK HEALTHCARE
 
P/E (TTM) x 76.0 18.3 416.3% View Chart
P/BV x 21.4 1.5 1,464.5% View Chart
Dividend Yield % 0.0 1.1 -  

Financials

 ASTRAZENECA PHARMA   TTK HEALTHCARE
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
TTK HEALTHCARE
Mar-19
ASTRAZENECA PHARMA/
TTK HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs1,2781,215 105.2%   
Low Rs883610 144.7%   
Sales per share (Unadj.) Rs228.4444.4 51.4%  
Earnings per share (Unadj.) Rs10.417.2 60.1%  
Cash flow per share (Unadj.) Rs16.327.6 58.9%  
Dividends per share (Unadj.) Rs05.00 0.0%  
Dividend yield (eoy) %00.5 0.0%  
Book value per share (Unadj.) Rs98.8177.9 55.5%  
Shares outstanding (eoy) m25.0014.13 176.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.72.1 230.3%   
Avg P/E ratio x104.252.9 197.0%  
P/CF ratio (eoy) x66.433.0 201.2%  
Price / Book Value ratio x10.95.1 213.3%  
Dividend payout %029.0 0.0%   
Avg Mkt Cap Rs m27,00812,894 209.5%   
No. of employees `0001.42.3 58.7%   
Total wages/salary Rs m1,5351,307 117.5%   
Avg. sales/employee Rs Th4,210.92,715.7 155.1%   
Avg. wages/employee Rs Th1,132.2565.3 200.3%   
Avg. net profit/employee Rs Th191.1105.4 181.3%   
INCOME DATA
Net Sales Rs m5,7106,279 90.9%  
Other income Rs m12378 158.1%   
Total revenues Rs m5,8336,356 91.8%   
Gross profit Rs m463496 93.4%  
Depreciation Rs m147147 100.5%   
Interest Rs m034 0.0%   
Profit before tax Rs m438393 111.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m179149 120.1%   
Profit after tax Rs m259244 106.3%  
Gross profit margin %8.17.9 102.7%  
Effective tax rate %40.837.9 107.7%   
Net profit margin %4.53.9 116.9%  
BALANCE SHEET DATA
Current assets Rs m3,2092,717 118.1%   
Current liabilities Rs m2,0701,571 131.7%   
Net working cap to sales %20.018.3 109.3%  
Current ratio x1.61.7 89.6%  
Inventory Days Days7232 225.0%  
Debtors Days Days3547 74.9%  
Net fixed assets Rs m790991 79.7%   
Share capital Rs m50141 35.4%   
"Free" reserves Rs m2,4192,373 102.0%   
Net worth Rs m2,4692,514 98.2%   
Long term debt Rs m03 0.0%   
Total assets Rs m4,6054,158 110.8%  
Interest coverage xNM12.6-  
Debt to equity ratio x00 0.0%  
Sales to assets ratio x1.21.5 82.1%   
Return on assets %5.66.7 84.3%  
Return on equity %10.59.7 108.3%  
Return on capital %17.716.9 104.7%  
Exports to sales %03.6 0.0%   
Imports to sales %00.5 0.0%   
Exports (fob) Rs mNA225 0.0%   
Imports (cif) Rs mNA31 0.0%   
Fx inflow Rs m300225 133.0%   
Fx outflow Rs m2,01571 2,833.5%   
Net fx Rs m-1,715154 -1,113.2%   
CASH FLOW
From Operations Rs m88173 50.8%  
From Investments Rs m-9497 -97.0%  
From Financial Activity Rs mNA-307 0.0%  
Net Cashflow Rs m-6-38 15.1%  

Share Holding

Indian Promoters % 0.0 65.4 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 0.3 3.7 8.1%  
FIIs % 15.7 5.2 301.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 25.8 35.3%  
Shareholders   12,856 12,723 101.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   DR. REDDYS LAB  IPCA LABS  NATCO PHARMA  SUN PHARMA  PIRAMAL ENTERPRISES  

Compare ASTRAZENECA PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Strengthening Rupee, Inflation & Factory Output Data, and Top Stocks in Action Today(Pre-Open)

On Friday, Indian share markets witnessed most of the buying interest during closing hours and ended on a strong note.

Related Views on News

TTK HEALTHCARE Announces Quarterly Results (1QFY20); Net Profit Down 53.8% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, TTK HEALTHCARE has posted a net profit of Rs 36 m (down 53.8% YoY). Sales on the other hand came in at Rs 2 bn (up 3.2% YoY). Read on for a complete analysis of TTK HEALTHCARE's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

TTK HEALTHCARE 2018-19 Annual Report Analysis (Annual Result Update)

Jul 18, 2019 | Updated on Jul 18, 2019

Here's an analysis of the annual report of TTK HEALTHCARE for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of TTK HEALTHCARE. Also includes updates on the valuation of TTK HEALTHCARE.

TTK HEALTHCARE Announces Quarterly Results (4QFY19); Net Profit Down 38.0% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, TTK HEALTHCARE has posted a net profit of Rs 50 m (down 38.0% YoY). Sales on the other hand came in at Rs 1 bn (down 3.8% YoY). Read on for a complete analysis of TTK HEALTHCARE's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Insider Buying Alert: Promoters Increase Stake in 8 High-Quality Smallcaps(Profit Hunter)

Sep 3, 2019

Insiders have increased their stakes in eight Hidden Treasure recommendations. Should you follow them?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Sep 13, 2019 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 5-YR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS